Lung Cancer Clinical Trial
Official title:
Using an Interactive Voice Response Telephone System in the Assessment and Management of Symptoms in Advanced Lung Cancer Patients Receiving Chemotherapy
Primary Objectives:
- To compare the effectiveness of an interactive voice response (IVR) telephone
triage/feedback system versus an interactive voice response telephone system with
assessment only in monitoring and managing symptoms in patients with advanced non small
cell lung cancer (NSCLC).
- To compare differences in mood and quality of life variables of patients using the IVR
triage/feedback system versus IVR assessment only.
- To compare the healthcare utilization (emergency visits, admissions, length of stay for
hospitalizations for uncontrolled symptoms) of patients using the IVR triage/feedback
system versus IVR assessment only.
You will be asked to complete several questionnaires during a visit to the Thoracic Clinic.
These questionnaires measure physical and emotional symptoms, and quality of life.
Completing the questionnaires takes about 30-45 minutes. The research nurse will also teach
you how to use the telephone system for reporting symptoms. You will tell the research nurse
when the most convenient times for the telephone calls and the telephone system will be set
up to call at those times.
It is not clear at this time whether the telephone symptom evaluation is better than the
usual plan that doctors and nurses follow for asking about symptoms. For this reason, you
will be randomly picked (as in the toss of a coin) to be in one of two groups. The chance of
being in either one of the two programs is about equal.
Half of the patients will be assigned to the "telephone assessment system plus triage"
group. If you are assigned to this group, you will report symptoms to the telephone system
and the doctor or nurse at M.D. Anderson will be notified when a symptom is severe. You will
also be encouraged to report all symptoms to their doctor and nurse at M.D. Anderson.
Half of the patients will be assigned to the "telephone assessment only" group. If you are
assigned to this group, your symptom information will only be given through the telephone
system. You will also be encouraged to report all symptoms directly to your doctor and nurse
at M.D. Anderson. Your physician may request information from the telephone system.
If you are assigned to this "telephone assessment only" group, the telephone system will
call you twice a week during 2 cycles of chemotherapy. It is programmed to ask you to rate
your symptoms and how much the symptoms interfere in your life. Rating symptoms using the
telephone system takes less than five minutes for each call.
After each chemotherapy cycle, you and patients in both groups will be asked to fill out
questionnaires during a clinic visit. The questionnaires are used to measure emotional
symptoms and quality of life. Completing the questionnaires takes about 15-30 minutes. Your
medical charts will also be reviewed and information collected about medical history.
If you have agreed to participate in the companion caregiver study, the study staff will use
your demographic and clinical data to study the influence of your symptoms on your
caregiver's physical and mental health.
This is an investigational study. About 100 will be enrolled at M.D. Anderson Cancer Center.
A total of 136 patients will take part in this multicenter study.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|